Trial Details

WITHDRAWN
Basic Information
Clinical ID c1708
Identifier NCT04643483
Trial Title A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease
Trial URL Visit Original Page
Study Information
Study Results

NO

Conditions Crohn's Disease
Interventions DRUG: Certolizumab pegol|DRUG: Adalimumab|DRUG: Placebo
Participant Information
Sponsor UCB Biopharma SRL
City -
Country/Region -
Enrollment Criteria
Sex Requirement ALL
Age Requirement CHILD
Study Design
Study Type INTERVENTIONAL
Phase PHASE3
Time Information
Start Date 2021-06
Primary Completion Date 2023-09
Completion Date 2026-04